THC Stock Tenet Healthcare (THC, $257.93) entered a monthly bullish trend. Expect an Uptrend continuation
at Tickeron.com
Loading...
Tenet Healthcare Corp (THC, $257.93) is predicted by A.I.dvisor to grow by to $268.25 or more within the next month. Keeping in mind similar previously-analyzed scenarios where the stock trended up during the month, the odds of an Uptrend continuation are
THC sees its Stochastic Oscillator climbs out of oversold territory
On September 28, 2026, the Stochastic Oscillator for THC moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 50 instances where the indicator left the oversold zone. In 42 of the 50 cases the stock moved higher in the following days. This puts the odds of a move higher at over 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
THC moved above its 50-day moving average on September 25, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.40% 3-day Advance, the price is estimated to grow further. Considering data from situations where THC advanced for three days, in 266 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
THC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The 10-day RSI Indicator for THC moved out of overbought territory on August 25, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 50 similar instances where the indicator moved out of overbought territory. In 30 of the 50 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on THC as a result. In 46 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where THC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 66%.
The Aroon Indicator for THC entered a downward trend on September 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 18 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. THC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 64 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.490) is normal, around the industry mean (208.196). P/E Ratio (10.039) is within average values for comparable stocks, (175.365). Projected Growth (PEG Ratio) (1.801) is also within normal values, averaging (2.496). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.022) is also within normal values, averaging (2.688).